Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

FDA Review of Altabax Promotional Material

In April 2010, the U.S. Food and Drug Administration issued a warning letter to GlaxoSmithKline about the promotion of its Altabax skin infection ointment. The FDA reviewed a sales brochure known as a “slim jim” sales aid which discussed Altabax and found it “false or misleading.” The FDA said the brochure “broadens the indication of Altabax, makes unsubstantiated superiority claims, and omits and minimizes important risk information associated with Altabax. Thus, the slim jim misbrands the drug in violation of the Federal Food, Drug, and Cosmetic Act….These violations are concerning from a public health perspective because they suggest that Altabax is safer or more effective than has been demonstrated by substantial evidence or substantial clinical experience.”

Misconduct Type
Health
Enforcement Agency
Health and Human Services
Contracting Party
None
Court Type
N/A
Disposition
Investigative Finding
Date of FDA Warning Letter
4/19/2010
Contractors Involved Penalty
Total
GlaxoSmithKline $0
Further Information Released
FDA Warning Letter 7/14/2010

Federal Contractor Misconduct Database